文献速递白血病造血干细胞移植与细胞治疗

贫困和社区机会对接受CD19靶向CAR-T细胞治疗的儿童结局的影响

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy.
PubMed 文献 · Blood · 2023-01-01

该研究分析了2012至2020年接受CD19靶向CAR-T细胞治疗的206例复发/难治性CD19阳性急性淋巴细胞白血病/淋巴母细胞淋巴瘤患者,发现家庭贫困和社区机会低与完全缓解率无显著差异,但低机会社区患者复发风险增加(校正HR 2.3,95%CI 1.3-4.1),而死亡风险无差异(校正HR 1.2,95%CI 0.6-2.4)。

要点

  • 206例患者中35.9%暴露于家庭贫困,24.9%社区机会低。
  • 低机会社区患者复发风险增加(校正HR 2.3,95%CI 1.3-4.1)。
  • 完全缓解率和总生存率在不同社会经济地位间无显著差异。

核心结论

  • 成功接受CAR-T细胞治疗的儿童中,无论替代社会经济地位和社区机会如何,完全缓解率和总生存率均公平。
  • 来自更富裕家庭和社区的患者接受CAR-T治疗时疾病负担更高。
  • 需要进一步研究多中心结局和临床试验环境之外的获取差异。

研究设计与样本

  • 研究纳入2012至2020年在CD19靶向CAR-T细胞临床试验或接受商业替沙基仑赛治疗的复发/难治性CD19阳性急性淋巴细胞白血病/淋巴母细胞淋巴瘤患者,共206例,年龄1至29岁。
  • 家庭贫困暴露定义为仅享有医疗补助保险;低社区机会由儿童机会指数定义。

主要发现

  • 206例患者中35.9%暴露于家庭贫困,24.9%社区机会低。
  • 未暴露于家庭贫困或低机会社区的患者更可能接受CAR-T治疗时疾病负担高(>25%),与较不富裕患者相比(38% vs 30%;37% vs 26%)。
  • 完全缓解率为93%,家庭贫困(P = .334)或社区机会(P = .504)间无显著差异。
  • 多变量分析中,低机会社区患者复发风险增加(P = .006;校正HR 2.3;95%CI 1.3-4.1),死亡风险无差异(P = .545;校正HR 1.2;95%CI 0.6-2.4)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究多中心结局和临床试验环境之外的获取差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children living in poverty experience excessive relapse and death from newly diagnosed acute lymphoblastic leukemia (ALL). The influence of household poverty and neighborhood social determinants on outcomes from chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory (r/r) leukemia is poorly described. We identified patients with r/r CD19+ ALL/lymphoblastic lymphoma treated on CD19-directed CAR T-cell clinical trials or with commercial tisagenlecleucel from 2012 to 2020. Socioeconomic status (SES) was proxied at the household level, with poverty exposure defined as Medicaid-only insurance. Low-neighborhood opportunity was defined by the Childhood Opportunity Index. Among 206 patients aged 1 to 29, 35.9% were exposed to household poverty, and 24.9% had low-neighborhood opportunity. Patients unexposed to household poverty or low-opportunity neighborhoods were more likely to receive CAR T-cell therapy with a high disease burden (>25%), a disease characteristic associated with inferior outcomes, as compared with less advantaged patients (38% vs 30%; 37% vs 26%). Complete remission (CR) rate was 93%, with no significant differences by household poverty (P = .334) or neighborhood opportunity (P = .504). In multivariate analysis, patients from low-opportunity neighborhoods experienced an increased hazard of relapse as compared with others (P = .006; adjusted hazard ratio [HR], 2.3; 95% confidence interval [CI], 1.3-4.1). There was no difference in hazard of death (P = .545; adjusted HR, 1.2; 95% CI, 0.6-2.4). Among children who successfully receive CAR T-cell therapy, CR and overall survival are equitable regardless of proxied SES and neighborhood opportunity. Children from more advantaged households and neighborhoods receive CAR T-cell therapy with a higher disease burden. Investigation of multicenter outcomes and access disparities outside of clinical trial settings is warranted.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Newman H, Li Y, Liu H, et al. Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Blood. 2023. PMID: 36351239. doi:10.1182/blood.2022017866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。